Enrofloxacin is a fluoroquinolone antibiotic used to treat bacterial infections in veterinary medicine. It is effective against both Gram-positive and Gram-negative bacterial infections affecting various livestock and companion animal species. Enrofloxacin helps in effectively treating infections caused by pathogens such as Escherichia coli, Staphylococcus spp, and Pasteurella spp. in poultry and swine. The global Enrofloxacin Market is estimated to be valued at US$ 190 million in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
The increasing demand for antibiotics in the veterinary industry represents a key market opportunity for the growth of the Global Enrofloxacin Market Size over the forecast period. According to the United States Department of Agriculture, global meat consumption is projected to grow by over 25% between 2018 and 2028, with the largest growth projected from developing regions. The rise in the population and purchasing power of people has increased the demand for meat and meat products across the world. This strong demand acts as a driver for the livestock industry, which uses antibiotics such as enrofloxacin to treat bacterial infections prevalent among livestock animals including cattle, pigs, and poultry. The growing livestock industry globally will correspond to an increase in demand for veterinary antibiotics including enrofloxacin during the forecast period.

Porter's Analysis

Threat of new entrants: The pharmaceutical industry requires huge R&D investments and regulatory approvals which make it difficult for new players to enter the market. Bargaining power of buyers: The buyers have moderate bargaining power as there are few alternatives available in the market. Bargaining power of suppliers: The suppliers have low to moderate bargaining power as there are multiple raw material suppliers in the market. Threat of new substitutes: New substitute products pose low threat as enrofloxacin offers unique benefits over other antibiotics. Competitive rivalry: The market is moderately competitive with the presence of key global and regional players.

SWOT Analysis

Strengths: Enrofloxacin is highly effective against a wide range of bacterial infections. It has minimal side effects.
Weaknesses: Development of antibiotic resistance against enrofloxacin. Requirement of prescription limits self-medication.
Opportunities: Potential for market growth in developing regions. Scope for new combination drug formulations.
Threats: Stringent regulatory environment. Susceptibility to price fluctuations of raw materials.

Key Takeaways

The global enrofloxacin market is expected to witness high growth.

Regional analysis: The Asia Pacific region dominates the global enrofloxacin market with countries like India and China accounting for major shares. Growing meat production in these countries coupled with rising awareness about animal health is fueling market growth. India is the largest producer and consumer of poultry meat which is providing impetus to demand for veterinary pharmaceuticals including enrofloxacin.

Key players operating in the enrofloxacin market are Bayer, Cadila Pharmaceuticals, New South Pharmaceuticals, SPL Group and Troikaa Pharmaceuticals. Bayer is one of the established players manufacturing enrofloxacin under the brand name Baytril. Cadila Pharmaceuticals offers generic enrofloxacin formulations. New entrants are focusing on combination drug formulations to strengthen their positions. Competition is expected to intensify further with stringent regulations and pricing pressures.

Get More Insights On This Topic: https://www.newswirestats.com/enrofloxacin-market-forecast-outlook-trend-2023-2030/